Medtronic Launches U.S. Trial For Predictive Glucose Monitor-Pump System
This article was originally published in The Gray Sheet
The single-arm pivotal trial is assessing the firm's next-generation diabetes system, which adds predictive algorithm features and a smaller sensor compared to the currently marketed MiniMed 530G low-glucose suspend device, marking another step towards an artificial pancreas, Medtronic says.
You may also be interested in...
The company touts the system as its latest breakthrough toward the development of an artificial pancreas. It can automatically suspend or resume insulin delivery based on pre-set thresholds.
CDRH has formed a close working partnership with Medtronic to facilitate quick approval for a next-generation insulation pump-glucose monitor, offering an illustration of what the center’s future plans might be for addressing devices with breakthrough potential.
Medtronic recently announced FDA approval of its MiniMed 530G low-glucose-suspend insulin pump, the first system approved in the U.S. that can automatically stop insulin delivery when blood glucose levels fall to a pre-set level.